Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies-Reference-Cited by-同舟云学术

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies

Published:2022-01 Issue:1 Volume:8 Page:
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:A&D Transl Res & Clin Interv

Author:

Pagan Fernando L.¹²,Torres‐Yaghi Yasar¹²,Hebron Michaeline L.¹,Wilmarth Barbara¹²,Turner R. Scott³,Matar Sara¹,Ferrante Dalila¹,Ahn Jaeil⁴,Moussa Charbel¹

Affiliation:

1. Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Lewy Body Dementia Association Research Center of Excellence Georgetown University Medical Center Washington DC USA

2. MedStar Georgetown University Hospital Movement Disorders Clinic Department of Neurology Washington DC USA

3. Memory Disorders Program Department of Neurology Georgetown University Medical Center Washington DC USA

4. Department of Biostatistics Bioinformatics and Biomathematics Georgetown University Medical Center Washington DC USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/trc2.12296

Reference46 articles.

1. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia

2. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

3. In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells

4. An update on dual Src/Abl inhibitors

5. Tau Phosphorylated at Tyrosine 394 is Found in Alzheimer's Disease Tangles and can be a Product of the Abl-Related Kinase, Arg

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes;Frontiers in Dementia;2024-08-16

2. c-KIT inhibitors reduce pathology and improve behavior in the Tg(SwDI) model of Alzheimer’s disease;Life Science Alliance;2024-07-15

3. Abelson Tyrosine Kinase Inhibitors in Parkinson's Disease and Lewy Body Dementia: A Systematic Review, Meta-analysis, and Meta-regression;Clinical Neuropharmacology;2024-05-22

4. Insights into the management of Lewy body dementia: a scoping review;Annals of Medicine & Surgery;2024-01-03

5. Lewy Body Dementia: An Overview of Promising Therapeutics;Current Neurology and Neuroscience Reports;2023-08-12